Posted in Board, Novacyt Group, Products, Uncategorized

COVID-19 diagnostic tests remain able to detect all published virus strains

Paris, France and Camberley, UK – 21 December 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the detection of a new variant of COVID-19 by the UK’s COVID-19 Genomics UK consortium, known as VUI-202012/01, the Company has carried out a detailed analysis of the mutations in

Visit Page
Posted in Board, Novacyt Group, Products, Uncategorized

Development of three tests for new strains of COVID-19 and avian influenza

Paris, France and Camberley, UK – 14 December 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of its research-use-only (RUO) polymerase chain reaction (PCR) test for a new strain of COVID-19 and the development of two new RUO PCR tests for avian influenza following recent outbreaks

Visit Page
Posted in Non classifié(e)

Développement de trois tests pour de nouvelles souches de la COVID-19 et de la grippe aviaire

Paris, France et Camberley, Royaume-Uni – 14 décembre 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste mondial du diagnostic clinique, annonce le lancement de son test de recherche (Research-Use-Only – RUO) d’amplification en chaîne par polymérase (PCR) pour une nouvelle souche de la COVID-19 et la mise au point de deux nouveaux tests PCR

Visit Page